v3.25.4
Segment, Geographic and Other Revenue Information - Revenues by Product - Footnotes (Details)
treatment_course in Millions, $ in Millions
2 Months Ended 3 Months Ended 12 Months Ended
Feb. 29, 2024
treatment_course
Sep. 29, 2024
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
treatment_course
Revenue from External Customer [Line Items]            
Total revenues [1]       $ 62,579 $ 63,627 $ 59,553
Paxlovid, EUA-Labeled [Member]            
Revenue from External Customer [Line Items]            
Reversal of revenue           $ 3,500
Estimated government emergency use authorization inventory to be returned to company, number of treatment courses | treatment_course           6.5
Favorable adjustment for government emergency use authorization inventory returned to the company during the period     $ 771   771  
Government emergency use authorization inventory returned to the company during the period, number of treatment courses | treatment_course 5.1          
Paxlovid, NDA-Labeled, U.S. Strategic National Stockpile [Member]            
Revenue from External Customer [Line Items]            
Revenues   $ 442        
Biopharma [Member]            
Revenue from External Customer [Line Items]            
Total revenues       61,199 62,400 $ 58,237
Biopharma [Member] | Specialty Care [Member]            
Revenue from External Customer [Line Items]            
Total revenues       17,546 16,652 14,988
Biopharma [Member] | Paxlovid, EUA-Labeled [Member]            
Revenue from External Customer [Line Items]            
Reversal of revenue           3,500
Favorable adjustment for government emergency use authorization inventory returned to the company during the period     $ 771      
Biopharma [Member] | Octagam [Member] | Specialty Care [Member]            
Revenue from External Customer [Line Items]            
Total revenues       $ 418 $ 509 $ 245
[1] Revenues are primarily attributed to countries based on the location of the customer.